JeanMarieTersakMD

Clinical Trials

• Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18

  Active, not recruiting

  Phase 3

• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2004 Feb 01

  Completed

  Phase 1

• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Start of enrollment: 2005 Jul 01

  Terminated

  Phase 2

• Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04

  Active, not recruiting

  Phase 3

• Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27

  Recruiting

• Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16

  Completed

• Childhood Cancer Survivor Study Start of enrollment: 1995 Jan 05

  Recruiting

  Roles: Contact, Principal Investigator

• Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22

  Completed

  Phase 2

• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01

  Completed

  Phase 1

• Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12

  Completed

  Phase 2

• Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31

  Completed

  Phase 1, Phase 2

• Stress Management Intervention for Mothers of Children With Cancer Start of enrollment: 2010 Sep 01

  Completed

  Not Applicable

• Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01

  Completed

  Phase 2

• Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16

  Completed

  Phase 1, Phase 2

• VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01

  Completed

  Phase 1

• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11

  Active, not recruiting

  Phase 2, Phase 3

• A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11

  Completed

  Phase 1

• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2020 Oct 13

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Start of enrollment: 2020 Oct 19

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Start of enrollment: 2017 Aug 08

  Recruiting

  Phase 3

  Roles: Principal Investigator

• A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects Start of enrollment: 2019 Oct 21

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Start of enrollment: 2014 Aug 08

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Apr 17

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors Start of enrollment: 2017 Dec 06

  Active, not recruiting

  Roles: Principal Investigator

• Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Start of enrollment: 2017 Nov 29

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Start of enrollment: 2017 Jul 31

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study Start of enrollment: 2020 Dec 07

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Start of enrollment: 2020 Jul 21

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2020 Jul 20

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Start of enrollment: 2019 Nov 08

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2019 Aug 29

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2019 Aug 29

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Nov 28

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Start of enrollment: 2018 May 14

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Start of enrollment: 2017 May 25

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2021 May 03

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Start of enrollment: 2018 Sep 09

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Aug 23

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery Start of enrollment: 2020 Oct 07

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Project: Every Child for Younger Patients With Cancer Start of enrollment: 2015 Nov 03

  Recruiting

  Roles: Principal Investigator

• Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Start of enrollment: 2022 Apr 01

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma Start of enrollment: 2022 Aug 04

  Recruiting

  Phase 3

  Roles: Principal Investigator

• A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Start of enrollment: 2021 Sep 14

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer Start of enrollment: 2022 Apr 08

  Recruiting

  Roles: Principal Investigator

• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Start of enrollment: 2023 May 11

  Recruiting

  Phase 3

  Roles: Principal Investigator

• A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia Start of enrollment: 2023 Jun 12

  Recruiting

  Roles: Principal Investigator

• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Start of enrollment: 2023 Mar 03

  Suspended

  Phase 2, Phase 3

  Roles: Principal Investigator

• A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma Start of enrollment: 2023 Aug 18

  Recruiting

  Roles: Principal Investigator

• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma Start of enrollment: 2024 Apr 19

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Join now to see all